LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Home・Elenco Azioni・Savara Inc

Savara Inc

Chiusa

SettoreSettore sanitario

2.98 0.68

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.74

Massimo

2.99

Metriche Chiave
By Trading Economics
Entrata	-4.8M -29M
Vendite	272K 272K
EPS	-0.13
Margine di Profitto	-10,677.941
Dipendenti	59
EBITDA	-4.8M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+184.11% upside

Dividendi
By Dow Jones
Utili prossimi	8 ago 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	36M 521M
Apertura precedente	2.3
Chiusura precedente	2.98

Notizie sul Sentiment di mercato

By Acuity

79%

21%

364 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

2.76 / 2.84 Supporto e resistenza

Savara Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2025, 23:40 UTC

Azioni calde

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mag 2025, 23:33 UTC

I principali Market Mover

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mag 2025, 23:25 UTC

I principali Market Mover

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mag 2025, 23:25 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 22:58 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 21:35 UTC

Utili

Cisco Systems Names Patterson as CFO, Patel as President

14 mag 2025, 23:59 UTC

Discorsi di Mercato

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mag 2025, 23:49 UTC

Discorsi di Mercato

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Gains on Possible Technical Recovery -- Market Talk

14 mag 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mag 2025, 23:10 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 23:07 UTC

Utili

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mag 2025, 23:00 UTC

Notizie principali

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mag 2025, 22:43 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 22:34 UTC

Utili

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mag 2025, 22:33 UTC

Utili

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mag 2025, 22:23 UTC

Notizie principali

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mag 2025, 22:15 UTC

Utili

Correction to Cisco Earnings Article -- WSJ

14 mag 2025, 21:48 UTC

Utili

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mag 2025, 21:37 UTC

Utili

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Savara Inc Previsione

Obiettivo di Prezzo

By TipRanks

184.11% in crescita

Previsioni per 12 mesi

Media 8.58 USD 184.11%

Alto 16 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Savara Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Savara Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

2.76 / 2.84Supporto e resistenza

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

364 / 382 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.